Lupus Nephritis

FDA: Studies Underway to Evaluate Chloroquine for COVID-19

Publish Date March 23, 2020

The FDA announced that it is working closely with other government agencies and academic centers to investigate the potential use of chloroquine for the treatment of coronavirus disease 2019 (COVID-19).

Antimalarials May Cut Risk for Type 2 Diabetes in Lupus Patients

Publish Date March 5, 2020

T2DM risk reduced by 39 percent for those with high adherence to antimalarial therapy for managing lupus.

Low Income May Increase Risk for Specific Glomerular Diseases

Publish Date February 25, 2020

Lower income associated with higher incidence of lupus nephritis, ANCA-related glomerulonephritis.

Renal Arteriosclerosis Develops Prematurely in Lupus Nephritis

Publish Date January 13, 2020

A study found that renal arteriosclerosis develops 2 decades earlier in patients with lupus nephritis compared with healthy age-matched controls.

Belimumab Associated With Meaningful Improvement in Lupus Nephritis Trial

Publish Date December 25, 2019

GlaxoSmithKline announced positive results from the phase 3 BLISS-LN trial of belimumab for the treatment of active lupus nephritis in adult patients.

Itolizumab Receives Fast Track Status for Lupus Nephritis

Publish Date December 16, 2019

The FDA has granted Fast Track designation for itolizumab (EQ001; Equillium) for the treatment of lupus nephritis.

Voclosporin Superior to Standard of Care in Lupus Nephritis Trial

Publish Date December 12, 2019

Voclosporin was found to be superior to standard-of-care treatment in patients with lupus nephritis, according to data from the phase 3 AURORA trial.

Biopsy-Informed Management Safely, Accurately Predicts Flares in Lupus Nephritis

Publish Date September 13, 2019

This study reports the long-term renal outcomes of kidney biopsies performed at prespecified intervals to determine the safety and accuracy of tapering of maintenance immunosuppression.

Obinutuzumab Gets Breakthrough Status for Treatment of Lupus Nephritis

Publish Date September 19, 2019

The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to obinutuzumab (Genentech), a CD20-directed cytolytic antibody, for the treatment of adults with lupus nephritis. The designation was based on data from the phase 2 NOBILITY study that compared the efficacy and safety of obinutuzumab, in combination with mycophenolate mofetil (MMF) or mycophenolic acid…

Good Renal Transplant Outcomes Reported in Lupus Nephritis Cases

Publish Date August 23, 2019

In a small study, patients with lupus nephritis who underwent renal transplantation had 5-year graft and patient survival rates of 76.3% and 92.5%, respectively.